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Background: Octaplas is a solvent/detergent-treated, pooled plasma used for the
management of preoperative or bleeding patients who require replacement of single
or multiple coagulation factors. The aim of this post-marketing study was to collect
real-world data on octaplas treatment in pediatric patients, with the primary focus
being safety.
Methods: This was an open-label, multicenter, phase IV study conducted in patients
<16 years old who required replacement of multiple coagulation factors due to liver
dysfunction associated with coagulopathy and/or required cardiac surgery or liver
surgery. Octaplas was administered intravenously based on ABO-group compatibility.
The primary endpoints included the incidence of serious adverse events (SAEs), adverse
drug reactions (ADRs), thrombotic events (TEs), thromboembolic events (TEEs) and
hyperfibrinolytic events (HFEs).
Results: A total of 50 patients were enrolled (≤2 years old, n = 37; >2 years
old, n = 13; female, n = 24) and 49 patients completed the study. Indications
for the use of octaplas included planned cardiac surgery (n = 40, 80.0%),
liver transplant surgery (n = 5, 10.0%) and liver dysfunction (n = 5, 10.0%).
No ADRs, HFEs or treatment-related TEs and TEEs occurred during the study.
Five patients had SAEs, one of which was fatal (iatrogenic injury). Other SAEs
included hemorrhage, hypotension, hemorrhagic shock, coronary artery hemorrhage,
intracardiac thrombus, supraventricular tachycardia, portal vein thrombosis and
respiratory failure (1 each). None of the SAEs were considered to be related to octaplas.
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Conclusions: Results of the present study support the use of octaplas in the
management of preoperative or bleeding pediatric patients who require replacement of
multiple plasma coagulation factors.
Clinical Trial Registration: ClinicalTrials.gov identifier: NCT02050841.
Keywords: bleeding, neonate, octaplas, pediatric, post-marketing, safety, surgery
INTRODUCTION
Correction of abnormal coagulation profiles in non-bleeding
patients is the most common indication for plasma transfusion
(1, 2). Clinical practice guidelines recommend plasma
transfusion in children and neonates with an abnormal
coagulation profile and clinically significant bleeding or prior
to invasive procedures that have a high risk of significant
bleeding (3).
Several types of plasma products are available for transfusion,
including fresh frozen plasma (FFP), plasma frozen within 24 h
(FP24) and solvent/detergent-treated plasma (SDP) (4, 5). FFP
and FP24 units are collected from a single donor, which results
in a significant variability in coagulation factor levels between
individual units (6). In contrast, SDP is pooled from multiple
units collected from different donors, resulting in significantly
lower variability in coagulation factor content compared with
FFP and FP24 (7–9). This difference in coagulation factors results
in greater variability in the generation of thrombin with FFP
and FP24 compared with SDP (6). Also, the solvent/detergent
treatment during the manufacturing of SDP inactivates any
lipid-enveloped viruses, such as human immunodeficiency virus,
hepatitis B and C, and Zika virus that may be present in
the donated plasma (10–12). Compared with FFP, SDP is
practically cell free, and contains significantly lower residual
platelet concentrations and negligible amounts of microparticles
due to its manufacturing process (6).
Octaplas (Octapharma AG, Austria) is a blood group-specific
SDP prepared from 630 to 1520 single-donor FFP units. It is also
marketed as octaplasLG, octaplasma, omniplas and other trade
names in various countries. In 2013 octaplas was approved in the
USA, and is indicated for the replacement of multiple coagulation
factors in patients with liver disease or who are undergoing
cardiac surgery or liver transplant and is also indicated for
therapeutic plasma exchange (TPE) in patients with thrombotic
thrombocytopenic purpura (13). The aim of this post-marketing
study was to collect real-world data on octaplas treatment in
pediatric patients, with the primary focus being safety.
MATERIALS AND METHODS
Design and Patients
This was an open-label, multicenter, post-marketing phase IV
study that included pediatric patients aged <16 years who
required replacement of multiple coagulation factors due to
liver dysfunction associated with coagulopathy or required
coagulation factors prophylaxis prior to cardiac surgery or liver
surgery (ClinicalTrials.gov identifier: NCT02050841). Patients
were identified for potential enrollment in the study by
monitoring for plasma orders by the clinical team. Those
who were deemed likely to require an intra-operative plasma
infusion were also invited to participate, but were excluded
from the analysis if they subsequently did not receive plasma
(i.e., screening failure). The main exclusion criteria were:
history of hypersensitivity reactions to blood or plasma-derived
products or to any excipient of octaplas; homozygous congenital
deficiency of protein S; immunoglobulin A deficiency with
documented antibodies against immunoglobulin A; congenital
factor deficiencies or platelet disorders; use of any plasma product
other than octaplas within 72 h of the first octaplas infusion;
extracorporeal membrane oxygenation at the time when plasma
for the first infusion episode was ordered by the treating
physician; expected transfusion of >40 mL/kg of all blood
products in a 24-h period; TPE; and premature birth, defined
as gestation <37 weeks. In addition, plasma replacement >72 h
after the end of cardiac surgery was an exclusion criterion for
patients who did not have coagulopathy due to liver dysfunction,
i.e., a patient requiring substitution of coagulation factors, due
to liver dysfunction, more than 72 h after surgery was eligible
for enrollment.
The study consisted of a screening phase, pre-infusion
assessments, a 72-h treatment period and a 72-h safety follow-
up period. A final examination was conducted at the end of the
safety follow-up period.
This study was carried out in accordance with the
recommendations of the local Institutional Review Boards
at participating institutions. Institutional Review Board
approvals for the protocol have been obtained. All subjects gave
written informed consent in accordance with the Declaration
of Helsinki.
Treatments
Octaplas was administered intravenously at the investigational
site by study staff based on ABO-group compatibility. In urgent
cases and in cases where the same blood group was not available,
blood group AB was used.
An infusion episode was defined as administration of any
amount of octaplas, with ≤60min between two individual
infusions. The exact dose, number of infusion episodes and total
volume of octaplas depended on the clinical setting. Normal
infusions were defined as all non-bypass priming infusions
received by the study population.
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The following concomitant therapies were permitted:
intravenous calcium-gluconate in patients with hypocalcemia
due to presumed citrate toxicity; intravenous antihistamines
and glucocorticoids in patients with allergic reactions; and
red blood cells, cryoprecipitate, and platelet transfusions, if
medically indicated. In addition, patients were permitted to
receive extracorporeal membrane oxygenation while on study if
it was initiated after enrollment. Single donor plasma (e.g., FFP,
FP24, thawed plasma, etc.) and TPE were prohibited.
Assessments and Endpoints
The primary endpoints of this study included the incidence
of serious adverse events (SAEs), adverse drug reactions
(ADRs), thrombotic events, thromboembolic events (TEEs), and
hyperfibrinolytic events. Primary endpoint events that occurred
between the start of the first infusion episode and the final
examination were recorded. ADRs or adverse events (AEs) were
elicited by clinicians from patients or their legal guardians using
non-leading questions per clinical trial protocol standards. For
example, “how have you been since the last evaluation?”, which
a parent/guardian would answer if their child or adolescent
was incapable of understanding or responding to the question.
AEs were coded using the Medical Dictionary for Regulatory
Activities. Study investigators graded the severity, seriousness
and causality of all AEs captured on the electronic case report
form. The Independent Data Monitoring Committee conducted
a quarterly review of the safety data, scrutinizing any ADRs or
SAEs. Non-serious AEs that were not related to octaplas were
not recorded. ADRs were defined as AEs for which a causal
relationship to octaplas could not be ruled out.
Secondary endpoints included: changes in hemostatic
parameters (international normalized ratio [INR], prothrombin
time [PT], activated partial thromboplastin time [aPTT],
thromboelastography [TEG]); volume (dose in mL/kg) of
octaplas used per infusion episode; medically significant
changes in vital signs (heart rate, respiratory rate, body
temperature, arterial saturation, and blood pressure); and
investigator’s assessment of overall safety for each patient
(excellent: octaplas was well-tolerated; moderate: ADRs
that were easily resolved or not clinically significant; poor:
ADRs requiring significant medical intervention). Abnormal
hemostatic parameter values were those outside of the range
of normal for patients requiring plasma infusions for bleeding
indications, based on the investigator’s clinical experience. These
were classified as clinically significant if, in the opinion of the
investigator, they suggested a disease and/or organ toxicity that
was new or that worsened from baseline, or if they required
additional active management. Any abnormal values that did
not fulfill these criteria were classified by the investigator as not
clinically significant.
Blood samples were drawn within 6 h before the start of the
first infusion episode and between 30 and 60min after each
infusion episode. The following TEG parameters were recorded:
reaction time, time from the end of R until the clot reaches
20mm, slope between R and K, maximum amplitude of clot
strength, and estimated percentage lysis at 30 min.
Statistics
A total of 50 pediatric patients were to be recruited in this study
to provide adequate safety information in a reasonable amount
of time, as discussed and agreed by the study sponsor with the
United States Food and Drug Administration.
The safety analysis set included all patients who received ≥1
infusion of octaplas. The full analysis set was defined according to
the intent-to-treat principle and comprised all patients who were
included in the safety population and had data on the primary
endpoint variables. The per-protocol population included all
patients who completed the infusion episodes and the final
examination without major protocol deviations that could have
affected the study outcomes.
All data collected were summarized and presented
descriptively. Descriptive statistics, including the number
of cases, mean and standard deviation (SD), median, maximum,
and minimum were calculated for continuous variables.
For categorical variables, frequencies and proportions were
calculated. The denominator for these calculations was the total
number of patients in the analysis population unless otherwise
specified. No hypothesis testing was conducted because this was
a descriptive post-marketing study and not designed to be a
hypothesis-testing study. Pre- and post-infusion measurements
were compared only descriptively. All statistical calculations
were made using SAS (version 9.4).
RESULTS
Study Population
Between July 2015 and December 2017, 50 patients treated
at two study centers (Washington University at St Louis and
the University of Alabama at Birmingham) were screened and
enrolled in this study (Table 1). Of these, 37 patients were
neonates or infants (aged ≤2 years) and 13 were children or
adolescents (aged >2 years). Overall, 24 female and 26 male
patients were included; the proportion of male patients was
higher in the >2 years group (69.2%; Table 1). Replacement of
multiple coagulation factors was required due to planned cardiac
surgery (n = 40, 80.0%), orthotopic liver transplant (n = 5,
10.0%) and liver dysfunction associated with coagulopathy (n =
5, 10.0%). The latter included patients with a clinical diagnosis of
sepsis-related coagulopathy in four children (8.0%) and hypoxic-
ischemic encephalopathy in one (2.0%).
In total, 49 patients (98.0%) completed the study. One patient
(2.0%) was withdrawn from the study prematurely due to the use
of a prohibited treatment (FFP). The supply of octaplas at the
study site was not sufficient to meet the transfusion requirements
of this patient and FFP had to be used. Therefore, 50 patients were
included in the safety and full analysis sets, while 49 patients were
included in the per protocol population.
Extent of Exposure
All 50 patients included in the study had ≥1 infusion episode,
while 10 patients had two infusion episodes, five patients had
three infusion episodes and one patient had six infusion episodes.
The mean number of infusions did not appear to vary greatly
between age groups (2 in patients aged ≤2 years and 4 in those
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TABLE 1 | Demographic data, full analysis set.
Infants ≤2
years n = 37
Children >2
years n = 13
Total
n = 50
Age (years)
Mean ± SD 0.2 ± 0.6 7.2 ± 5.0 2.0 ± 4.0
Min, max 0, 2 3, 16 0, 16
Sexa
Male 17 (45.9%) 9 (69.2%) 26 (52.0%)
Female 20 (54.1%) 4 (30.8%) 24 (48.0%)
Ethnicitya
Hispanic or Latino 1 (2.7%) 0 1 (2.0%)
Not Hispanic or Latino 36 (97.3%) 13 (100.0%) 49 (98.0%)
Racea
White 28 (75.7%) 6 (46.2%) 34 (68.0%)
Black or African American 8 (21.6%) 6 (46.2%) 14 (28.0%)
Asian 1 (2.7%) 0 1 (2.0%)
Other 0 1 (7.7%) 1 (2.0%)
ABO Blood Groupa
A 13 (35.1%) 3 (23.1%) 16 (32.0%)
B 6 (16.2%) 3 (23.1%) 9 (18.0%)
AB 3 (8.1%) 1 (7.7%) 4 (8.0%)
O 15 (40.5%) 6 (46.2%) 21 (42.0%)
Height (cm)
Mean ± SD 63.1 ± 10.2 120.9 ± 28.3 78.1 ± 30.4
Min, max 46, 92 96, 171 46, 171
Weight (kg)
Mean ± SD 6.66 ± 2.7 33.58 ± 36.1 13.66 ± 21.6
Min, max 3.4, 14.0 12.7, 144.0 3.4, 144.0
BMI (kg/m2 )
Mean ± SD 16.15 ± 2.9 18.98 ± 9.5 16.88 ± 5.4
Min, max 11.5, 26.5 11.7, 49.2 11.5, 49.2
Indication for replacement of multiple coagulation factorsa
Cardiac surgery 31 (83.8%) 9 (69.2%) 40 (80.0%)
Liver transplant surgery 3 (8.1%) 2 (15.4%) 5 (10.0%)
Liver dysfunction
Sepsis-related coagulopathy 2 (5.4%) 2 (15.4%) 4 (8.0%)
Coagulopathy associated with HIE 1 (2.7%) 0 1 (2.0%)
Type of surgerya
Cardiac 31 (83.8%) 9 (69.2%) 40 (80.0%)
Orthotopic liver transplant 3 (8.1%) 2 (15.4%) 5 (10.0%)
None 3 (8.1%) 2 (15.4%) 5 (10.0%)
ECMO during surgerya
Yes 0 1 (7.7%) 1 (2.0%)
No 36 (97.3%) 12 (92.3%) 48 (96.0%)
CPB during surgerya
Yes 31 (83.8%) 9 (69.2%) 40 (80.0%)
No 5 (13.5%) 4 (30.8%) 9 (18.0%)
Concomitant medical conditionsa
Congenital, familial and genetic 30 (81.1%) 8 (61.5%) 38 (76.0%)
Ventricular septal defect 13 (35.1%) 4 (30.8%) 17 (34.0%)
Tetralogy of Fallot 16 (43.2%) 0 16 (32.0%)
Atrial septal defect 9 (24.3%) 2 (15.4%) 11 (22.0%)
Cardiac 18 (48.6%) 8 (61.5%) 26 (52.0%)
Respiratory, thoracic, and
mediastinal
16 (43.2%) 7 (53.8%) 23 (46.0%)
Infections and infestations 8 (21.6%) 5 (38.5%) 13 (26.0%)
Gastrointestinal 5 (13.5%) 5 (38.5%) 10 (20.0%)
aCategorial data are presented as n (%).
BMI, body mass index; CPB, cardiopulmonary bypass; ECMO, extracorporeal membrane
oxygenation; HIE, hypoxic-ischemic encephalopathy; SD, standard deviation.
TABLE 2 | Exposure to octaplas infusions, safety analysis set.
Infants ≤2
years n = 37
Children >2
years n = 13
Total
n = 50
Total number of
infusionsa
2.3 ± 0.9 3.8 ± 3.1 2.7 ± 1.8
Octaplas dose administered (mL/kg)a
Infusion episode 1 33.9 ± 21.1
(n = 37)
12.8 ± 5.8
(n = 13)
28.4 ± 20.6
(n = 50)
Infusion episode 2 15.3 ± 8.9
(n = 4)
29.9 ± 30.6
(n = 6)
24.1 ± 24.6
(n = 10)
Infusion episode 3 11.2 ± 3.5
(n = 3)
13.9 ± 0.9
(n = 2)
12.3 ± 2.9
(n = 5)
Dose of normal infusions (mL/kg)b,c
Infusion episode 1 12.9 [4–69] (n
= 12)
11.7 [3–26]
(n = 8)
11.7 [3–69]
(n = 20)
Infusion episode 2 14.0 [6–27]
(n = 4)
20.0 [7–90]
(n = 6)
14.2 [6–90]
(n = 10)
Infusion episode 3 10.4 [8–15]
(n = 3)
13.9 [13–15]
(n = 2)
13.2 [8–15]
(n = 5)
aData are presented as mean ± SD.
bData are presented as median [range].
cNormal infusions are those excluding octaplas use for priming the circuit for
cardiac bypass.
aged >2 years, Table 2). The mean octaplas dose and median
infusion dose (normal infusions) are shown for infusion episodes
1 to 3 in Table 2.
For infusion episodes 1 and 2, the median infusion rates
for normal infusions (excluding octaplas use for priming the
circuit for cardiac bypass) was 0.2 mL/kg/min and for infusion
episode 3 it was 0.1 mL/kg/min; infusion rates appeared similar
between age groups although no statistical comparison was
made (data not shown). In the 28 patients who had bypass
priming (all aged ≤2 years), the median dose administered
was 19.1 (6–38) mL/kg and the median infusion rate
was 143.2 mL/kg/min.
Safety
No ADRs were reported during the study. Overall, five patients
(10.0%) had a total of nine SAEs (Table 3), three patients aged
≤2 years and two patients aged >2 years. Of these patients,
four had congenital heart disease and were undergoing cardiac
surgery, while one had liver disease and was undergoing liver
transplant surgery. The proportions of male and female patients
who had SAEs were 11.5 and 8.3%, respectively. Of the five
patients who had SAEs during this study, four had a total of
five SAEs that were considered severe, while one patient had
four moderate-intensity SAEs. One patient had an SAE that
led to death (injury to the coronary artery). All of the SAEs
observed were considered by each site’s principal investigator to
be expected AEs that were related to the patients’ underlying
disease or surgical intervention. Therefore, none of the SAEs were
considered related to the study medication or led to a change
in its dose or withdrawal. There were no clinically significant
changes in vital signs between pre- and post-infusion, other
than those which may be expected in a patient undergoing
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TABLE 3 | Serious adverse events, safety analysis set.
Infants ≤2 years n = 37 Children >2 years n = 13 Total n = 50
SAEs n Patientsa SAEs n Patientsa SAEs n Patientsa
Any 3 3 (8.1%) 6 2 (15.4%) 9 5 (10.0%)
Hemorrhage 1 1 (2.7%) 0 0 1 1 (2.0%)
Hypotension 0 0 1 1 (7.7%) 1 1 (2.0%)
Hemorrhagic shock 1 1 (2.7%) 0 0 1 1 (2.0%)
Coronary artery hemorrhage 0 0 1 1 (7.7%) 1 1 (2.0%)
Intracardiac thrombus 0 0 1 1 (7.7%) 1 1 (2.0%)
Supraventricular tachycardia 0 0 1 1 (7.7%) 1 1 (2.0%)
Portal vein thrombosis 1 1 (2.7%) 0 0 1 1 (2.0%)
Iatrogenic injury 0 0 1 1 (7.7%) 1 1 (2.0%)
Respiratory failure 0 0 1 1 (7.7%) 1 1 (2.0%)
an (%) for categorical data.
None of the SAEs was considered to be treatment-related.
SAE, serious adverse event.
cardiac surgery [e.g., hypertension is a frequent occurrence
postoperatively in cardiovascular interventions (14)].
No hyperfibrinolytic events were reported during the study.
There were two thrombotic events or TEEs reported in two
patients (4%). One patient aged ≤2 years and who was
undergoing a liver transplant had portal vein thrombosis. One
patient aged >2 years who had congenital heart disease and
was undergoing cardiac surgery had an intracardiac thrombus.
Neither of the TEEs was considered to be treatment-related.
For all 50 patients, the investigator assessment of safety
was “excellent.”
Treatment Response
Only three clinically significant abnormal hemostatic parameters
were observed pre- or post-transfusion during the first infusion
episode. One patient (2.0%) each showed a clinically significant
elevated INR pre- and post-infusion, and one patient (2.0%)
showed a clinically significant elevated aPTT value post-infusion.
As would be expected in this population, many patients
showed either no change in hemostatic parameters or changes
within the range of normal to non-clinically significant abnormal,
after the first infusion episode (Table 4). Following the first
infusion, the majority of patients had non-clinically significant
abnormal values post-infusion for INR (n = 36, 72.0%) and PT
(n= 38, 76.0%), while one-half of patients also had non-clinically
significant abnormal maximum amplitude of clot strength TEG
values post-infusion (n = 25, 50.0%). On the other hand, the
proportion of patients with non-clinically significant abnormal
values was numerically lower post-infusion than pre-infusion for
the following TEG parameters: reaction time (56.0 to 34.0%),
time from the end of R until the clot reaches 20mm (46.0 to
32.0%), slope between R and K (46.0 to 30.0%), and estimated
percentage lysis at 30min (2.0 to 0%). There was a concomitant
numerical increase in the proportion of patients with normal
values for each of these TEG parameters, from 32.0 to 58.0%
(reaction time), 42.0 to 60.0% (time from the end of R until the
clot reaches 20mm), 42.0 to 62.0% (slope between R and K), and
86.0 to 92.0% (estimated percentage lysis at 30 min).
DISCUSSION
The results of this open-label, multicenter, post-marketing
study provide clinical evidence supporting the use of octaplas
in critically ill pediatric patients who require replacement
of multiple coagulation factors due to major surgery or
acquired deficiencies associated with liver dysfunction. NoADRs,
hyperfibrinolytic events or treatment-related thrombotic events
and TEEs occurred during the study. Five patients had SAEs,
one of which was fatal (iatrogenic injury). None of the SAEs
were considered to be related to octaplas. Treatment response
appeared favorable in the majority of patients, with TEG values
that were either stable pre- vs. post-infusion or that changed
from abnormal (non-clinically significant) to normal pre- vs.
post-infusion for most TEG parameters.
While there were few unexpected clinically significant changes
in the hemostatic parameters, there were several parameters (e.g.,
INR, PT, aPTT) for which patients experienced increased values
post- vs. pre-infusion. As a result, there was a numerical increase
in the proportion of patients with non-clinically significant
abnormal hemostasis values after the first octaplas infusion
vs. pre-infusion. This may have occurred for two possible
reasons: first, patients who were bleeding may have continued
to consume coagulation factors and platelets while receiving
octaplas, and secondly, most of the patients in this study
(80%) underwent surgery with cardiopulmonary bypass and
the anticoagulation required may have affected post-transfusion
hemostasis parameters.
The results of this study add further evidence to the use
of octaplas in the pediatric population, which was previously
examined in a retrospective study (15). In that study, 41 critically
ill neonates received a mean ± SD dose of 18.4 ± 13.2 mL/kg
of octaplas and 15 pediatric patients with severe liver disease
received 38.0 ± 41.5 mL/kg of octaplas either before or after
liver transplant (15). Among the neonatal patients, 31 (75.6%)
received octaplas because they were considered to be at risk
of bleeding due to coagulopathy, eight (19.5%) because they
had clinical hemorrhage due to coagulopathy and two patients
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TABLE 4 | Patients with normal or abnormal hemostatic parameters before and
after the first infusion episode.
Parametera Pre-infusion Post-infusion
INR n = 47 n = 49
Normal 33 (66.0%) 12 (24.0%)
Abnormal NCS 13 (26.0%) 36 (72.0%)
PT, sec n = 47 n = 49
Normal 27 (54.0%) 11 (22.0%)
Abnormal NCS 20 (40.0%) 38 (76.0%)
aPTT, sec n = 47 n = 48
Normal 27 (54.0%) 24 (48.0%)
Abnormal NCS 19 (38.0%) 23 (46.0%)
TEG – R-time n = 44 n = 46
Normal 16 (32.0%) 29 (58.0%)
Abnormal NCS 28 (56.0%) 17 (34.0%)
TEG – K-time n = 44 n = 46
Normal 21 (42.0%) 30 (60.0%)
Abnormal NCS 23 (46.0%) 16 (32.0%)
TEG – alpha angle n = 44 n = 46
Normal 21 (42.0%) 31 (62.0%)
Abnormal NCS 23 (46.0%) 15 (30.0%)
TEG – MA n = 44 n = 46
Normal 32 (64.0%) 21 (42.0%)
Abnormal NCS 12 (24.0%) 25 (50.0%)
TEG – EPL30 n = 44 n = 46
Normal 43 (86.0%) 46 (92.0%)
Abnormal NCS 1 (2.0%) 0
aData are presented as n (%).
aPTT, activated partial thromboplastin time; EPL30, estimated percentage lysis at 30min;
INR, international normalized ratio; K-time, time from end of R until the clot reaches 20mm;
MA, maximum amplitude of clot strength; NCS, not clinically significant; PT, prothrombin
time; R-time, reaction time; TEG, thromboelastography.
had neither hemorrhage nor coagulopathy. Among the pediatric
patients, clinical conditions included autoimmune hepatitis,
cystic fibrosis, and hepatoblastoma in two patients each and liver
injury, portal hypertension and bleeding, and leishmaniasis in
one patient each. Following transfusion, significant reductions in
mean aPTT and PT, and an increase in fibrinogen were observed
in neonates, while increase in platelets was not statistically
significant. Significant changes were also observed in pediatric
patients, including reductions in aPTT and PT, while changes
in fibrinogen and platelets were not statistically significant, and
no clinical AEs associated with octaplas were observed in either
group (15). In another retrospective study of critically ill pediatric
patients undergoing TPE (n = 35), normalization of hemostatic
parameters with SDP with a low incidence of AEs (1.2%) was
reported (16).
In a report from a single hospital, 29 pediatric patients
(mean age: 6 years; range: 1 day to 15 years) received a
median of 10.0 mL/kg of octaplas (range: 6.3 to 21.1 mL/kg).
Indications for transfusion included priming of cardiopulmonary
bypass machine in 15 infusion episodes (29.4%), transplant-
associated thrombotic microangiopathy in 14 episodes (27.5%),
and active bleeding in 11 episodes (21.6%). The remaining
transfusions were performed due to prolonged PT and/or aPTT
with no further details provided (9.8%) and prior to a procedure
(9.8%). Mean PT decreased from 26 to 19 s and mean aPTT
decreased from 65 to 52 s (17). No adverse reactions were
observed (17).
Octaplas was compared with FFP in a retrospective analysis
that included 105 pediatric patients aged <2 years who
were undergoing tetralogy of Fallot repair (18). Most patients
received octaplas and FFP transfusions in the operating room
after cardiopulmonary bypass (93.8 and 85.0%, respectively).
Immediately after surgery, INR and aPTT were significantly
lower in patients who received octaplas than in those who
received FFP, and the proportion of patients who received
additional plasma transfusions was significantly higher in the
FFP group compared with the octaplas group. Furthermore,
the rate of postoperative infections requiring the use of
antibiotics was significantly higher in the FFP group compared
with the octaplas group, and no transfusion reactions were
observed in either group (18). In a secondary analysis
of a prospective, observational study that included 443
critically ill children who received plasma transfusions, FFP
and SDP were associated with similar reductions in INR
(p = 0.80). However, intensive care unit mortality was
significantly lower with SDP compared with FFP (14.5 vs. 29.1%,
p= 0.02) (4).
It is possible that the results obtained in the comparative
studies described above is due, in part, to the greater uniformity
of coagulation factor content of individual octaplas units
compared with FFP units (6, 7). Differences in coagulation
factor content are particularly important in patients who receive
transfusions of only one or very few units, such as children and
neonates. However, prospective comparative studies are required
to confirm the safety or efficacy advantages of octaplas observed
in these studies.
Our study had a number of limitations. Firstly, the study
included a relatively small number of patients and had a short
observation period. Also, no comparator group was included in
the study. As a result, it is difficult to judge the clinical relevance
of the treatment responses observed in our study. In contrast with
the previous studies of octaplas in children, which only assessed
INR/PT/aPTT/antithrombin III/activated clotting times, we also
assessed treatment response with various TEG parameters. Since
this study was designed to evaluate the safety of octaplas
treatment in pediatric patients, the efficacy outcomes were
presented descriptively without assessment of the relationship
between octaplas treatment and TEG measurements. Lastly,
the influence of patients’ ongoing blood loss, hemodynamic
status, the presence of sepsis or consumption coagulopathy, or
some concomitant drugs on efficacy outcomes were not taken
into account.
In conclusion, this post-marketing study provides
data on the safety of octaplas in critically ill pediatric
patients who require replacement of multiple coagulation
factors. The results of the present study and those of
previous studies of octaplas support its use in this
patient population.
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